JNEWS: Fenton, Dennis M. [MC1973] BoD Cirius Therapeutics

2018-Jan-04

https://www.prnewswire.com/news-releases/cirius-therapeutics-expands-board-of-directors-with-appointment-of-dennis-m-fenton-300577392.html

Cirius Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
NEWS PROVIDED BY Cirius Therapeutics 08:00 ET

KALAMAZOO, Mich. and SAN DIEGO, Jan. 4, 2018 /PRNewswire/ — Cirius Therapeutics, a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease, announced today that Dennis Fenton, Ph.D., has been appointed to the company’s board of directors as an independent member.

“Having an industry veteran of Dennis’ caliber join our board adds considerable depth and breadth to our company’s stellar leadership team,” said Bob Baltera, chief executive officer of Cirius. “We expect Dennis’ wealth of industry expertise will be invaluable as we continue to advance our lead product candidate through a Phase 2b trial in NASH and plan for the next phase of growth.”

Dr. Fenton brings more than forty years of experience in biopharmaceutical drug development and commercialization to this position. During a 25-year tenure at Amgen, he served as executive vice president of operations and held numerous additional executive leadership roles in operations, process development, sales, marketing, research, engineering and manufacturing.

Since retiring from Amgen in 2008, Dr. Fenton has served as an independent biotechnology consultant and serves on several public and private company boards including Portola Pharmaceuticals, Pfenex, Sienna Biopharmaceuticals, Omniox, and Modern Meadow. Dr. Fenton previously served on the boards of directors of Kythera, Amira, Hospira, Dendreon Corp., Xenoport and Genzyme Corporation. He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a Bachelor of Science in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.

“I look forward to working with the board and management team at Cirius,” said Dr. Fenton. “NASH is a critical disease affecting millions of people and I welcome the opportunity to help make a difference for these individuals.”

# – # – # – # – # 

Fenton, Dennis M. [MC1973] 

# – # – # – # – #  2018-Jan-04 @ 12:32  

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s